Two Years of Newborn Screening for Cystic Fibrosis in North Macedonia: First Experience.
Cystic fibrosis (CF)
Newborn screening (NBS)
cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations
Journal
Balkan journal of medical genetics : BJMG
ISSN: 1311-0160
Titre abrégé: Balkan J Med Genet
Pays: Poland
ID NLM: 9806959
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
There is a widely accepted consensus on the benefits of newborn screening (NBS) for cystic fibrosis (CF) in terms of reduced disease severity, improved quality of life, lower treatment burden, and reduced costs. More and more countries in the world are introducing NBS for CF as a national preventive health program. Newborn screening for CF was introduced in the Republic of North Macedonia (RNM) in April, 2019, after a pilot study of 6 months in 2018. A two-step immunoreactive trysinogen (IRT-IRT) algorithm is performed, and then a sweat test for confirmation/exclusion of the CF diagnosis when the IRT values were both over the cutoff (70.0 and 45.0 ng/mL, respectively). In cases with confirmed diagnosis of CF (a sweat chloride concentration >60.0 mmol/L) or with intermediate sweat test results (a sweat chloride concentration of between 30.0 and 59.0 mmol/L), CF transmembrane conductance regulator (CFTR) mutation analysis is performed. By the end of 2020, over a period of 27 months, including the pilot study period, a total number of 43,139 newborns were screened for CF. Seventeen (0.039%) newborns were diagnosed with CF. In all newly discovered CF cases by screening, the diagnosis was confirmed by determination of the CFTR mutations. The most common CFTR mutation, F508del, was found with an overall incidence of 70.6%. Other more frequent mutations were G542X (11.8%) and N1303K (5.9%). Four mutations were found in one CFTR allele each: G1349D, G126D, 457TAT>G and CFTRdupexon22, with the last one being newly discovered with unknown consequences. An incredibly large difference was found in the incidence of the disease between the Macedonian and Albanian neonatal population, with almost four time higher prevalence among Albanians (1:4530
Identifiants
pubmed: 34447658
doi: 10.2478/bjmg-2021-0015
pii: bjmg-2021-0015
pmc: PMC8366466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-46Informations de copyright
© 2021 Fustik S, Anastasovska V, Plaseska-Karanfilska D, Stamatova A, Spirevska L, Pesevska M, Terzikj M, Vujovic M, published by Sciendo.
Déclaration de conflit d'intérêts
Conflict of interest Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Références
J Cyst Fibros. 2009 May;8(3):153-73
pubmed: 19246252
J Cyst Fibros. 2016 May;15(3):302-8
pubmed: 27118577
J Cyst Fibros. 2014 May;13(3):267-74
pubmed: 24238947
Int J Neonatal Screen. 2020 Mar 04;6(1):18
pubmed: 33073015
Lancet Respir Med. 2016 Aug;4(8):653-661
pubmed: 27053341
J Pediatr. 2008 Aug;153(2):S4-S14
pubmed: 18639722
Pediatr Pulmonol. 2003 May;35(5):342-9
pubmed: 12687590
PLoS One. 2014 Nov 11;9(11):e112498
pubmed: 25386751
Eur Respir J. 2017 Nov 9;50(5):
pubmed: 29122914
Int J Neonatal Screen. 2020 Mar 12;6(1):19
pubmed: 33073016
Int J Neonatal Screen. 2020 Jul 03;6(3):54
pubmed: 33123635
Int J Neonatal Screen. 2020 Jan 31;6(1):8
pubmed: 33073006
J Pediatr. 2017 Feb;181S:S33-S44.e2
pubmed: 28129810
Thorax. 2020 Feb;75(2):123-131
pubmed: 31771956
Pediatrics. 2001 Jan;107(1):1-13
pubmed: 11134427
ERJ Open Res. 2018 Apr 20;4(2):
pubmed: 29692998
J Cyst Fibros. 2019 Nov;18(6):778-780
pubmed: 31027826
J Cyst Fibros. 2015 Nov;14(6):706-13
pubmed: 25630966
J Cyst Fibros. 2017 Mar;16(2):207-213
pubmed: 28043799
Balkan J Med Genet. 2019 Aug 28;22(1):35-40
pubmed: 31523618
J Cyst Fibros. 2014 May;13 Suppl 1:S23-42
pubmed: 24856775
J Cyst Fibros. 2018 Mar;17(2):153-178
pubmed: 29506920